8 Result(s)
-
Article
Response to imatinib mesylate of a gastrointestinal stromal tumor with very low expression of KIT
More than 90% of gastrointestinal stromal tumors (GISTs) express the receptor tyrosine kinase KIT, and activating mutations of the KIT gene are detectable in the vast majority of these tumors. Imatinib mesylat...
-
Chapter
Targeting mutant kinases in Gastrointestinal Stromal Tumors: A paradigm for molecular therapy of other sarcomas
-
Article
Gastrointestinal stromal tumours: origin and molecular oncology
Gastrointestinal stromal tumours (GISTs) are a family of tumours thought to arise from the interstitial cells of Cajal in the gastrointestinal tract. Recently,...
-
Article
Open AccessIntegrated genomic study of quadruple-WT GIST (KIT/PDGFRA/SDH/RAS pathway wild-type GIST)
About 10-15% of adult gastrointestinal stromal tumors (GIST) and the vast majority of pediatric GIST do not harbour KIT or platelet-derived growth factor receptor alpha (PDGFRA) mutations (J Clin Oncol 22:3813–38...
-
Article
Open AccessGenomic aberrations in cell cycle genes predict progression of KIT-mutant gastrointestinal stromal tumors (GISTs)
Activating mutations of the receptor tyrosine kinase KIT are early events in the development of most gastrointestinal stromal tumors (GISTs). Although GISTs generally remain dependent on oncogenic KIT during tumo...
-
Article
Colorectal Cancer-Associated Spontaneous Tumor Lysis Syndrome: a Case Report and Review of the Current Literature
-
Article
Open AccessCharacterizing advanced breast cancer heterogeneity and treatment resistance through serial biopsies and comprehensive analytics
Molecular heterogeneity in metastatic breast cancer presents multiple clinical challenges in accurately characterizing and treating the disease. Current diagnostic approaches offer limited ability to assess he...
-
Article
Open AccessMultiomics analysis of serial PARP inhibitor treated metastatic TNBC inform on rational combination therapies
In a pilot study, we evaluated the feasibility of real-time deep analysis of serial tumor samples from triple negative breast cancer patients to identify mechanisms of resistance and treatment opportunities as...
